BACKGROUND: @entity650 ( @entity650 ) blockage is a treatment strategy used in many inflammatory conditions. Trials in @entity1652 Spectrum Disorder (NMOSD) are ongoing. Secondary auto-immunity affecting the central nervous system (CNS) is well described with some biologic agents, mainly @entity5 @entity39 factor (TNF)-alpha inhibitors. These treatments can also aggravate @entity1 with known @entity15 ( @entity15 ). OBJECTIVES: To describe a case of a @entity1 who developed @entity15 using another biologic, @entity650 receptor antibody Tocilizumab. RESULTS: A 48-year-old @entity1 developed @entity15 while on treatment with Tocilizumab for @entity309 ( @entity309 ). This is the first published report of this association. It has obvious implications for NMOSD patients receiving anti- @entity650 therapy. Development of new white matter lesions suggestive of @entity15 in a @entity1 treated with anti- @entity650 therapy might represent an important complication of therapy. CONCLUSION: This case illustrates that Tocilizumab might cause secondary auto-immunity in CNS. It is important to be aware of this potential complication as anti- @entity650 therapy might become an option for the treatment NMOSD.

@entity15 arising during Tocilizumab therapy for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'woman', 'patient'] @entity650 :: ('3569', 'Gene') :: ['Interleukin-6', 'IL6'] @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis'] @entity1652 :: ('MESH:D009471', 'Disease') :: ['Neuromyelitis Optica'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity15 :: ('MESH:D009103', 'Disease') :: ['multiple sclerosis', 'MS'] @entity309 :: ('MESH:D001172', 'Disease') :: ['Rheumatoid Arthritis', 'RA']
@entity309 :: (MESH:D001172,Disease) :: ['rheumatoid arthritis']
